“Arana Therapeutics Limited (AAH) has commenced recruitment for a Phase II trial in psoriasis for its lead anti-TNF drug candidate ART621.” Other anti-TNF’s are already on the market, including Enbrel, Humira and Remicade. The psoriasis trial, to be conducted in Australia, is designed to help the company get the product approved one day for rheumatoid arthritis: “Arana chief executive John Chiplin said the strategy was to use information from the psoriasis trials to push along trials for the treatment of rheumatoid arthritis — a significantly larger market.”
[Further info: learn about 80 (!) other potential treatments being tested for psoriasis and psoriatic arthritis.]
Category: Biologics, Psoriasis Research
